Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

NCT01917656 on ClinicalTrials.gov · last registry update 2017-08-24

An unusually large phase 4: 343 participants, more than double the 75 typical for the stage. The sponsor logged completion for 1 September 2014. Primary outcome, as filed: Change in Fructosamine From Start of Ramadan to End of Ramadan. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 343
Started: 2014-01-09
Primary completion: 2014-09-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Fructosamine From Start of Ramadan to End of Ramadan

Conditions studied

Diabetes · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.